Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irrita. Technically, tianeptine differs from classical tricyclics and SSRIs by modulating glutamatergic neurotransmission and promoting neuroplasticity in limbic structures while exhibiting modulatory effects on monoaminergic tone via enhanced serotonin reuptake rather than inhibition. Pharmacologically relevant actions include agonism at mu opioid receptors that contributes to some of its clinical and abuse-related profiles, rapid gastrointestinal absorption with peak plasma concentrations typically reached within 1 to 2 hours after oral dosing, a relatively short elimination half life in the range of about 2 to 4 hours, and extensive hepatic metabolism to known metabolites that are excreted renally. Formulation variants include base and salt forms such as the sodium and oxalate salts; standard analytical characterization for pharmaceutical-grade material uses HPLC, MS and spectroscopic methods to confirm identity, potency and stability.
Parent: Tianeptine
Parent: Tianeptine/ Tianeptine Sodium
Pharmaceutical tianeptine API is routinely controlled to high purity with typical assay specifications aiming for greater than 98% stated purity for the active ingredient; total impurities are commonly limited to under 1.0% and individual unspecified impurities are controlled at low levels, frequently below 0.1 to 0.5% depending on regulatory and monograph requirements. Typical impurity and related-compound profiles include residual synthesis byproducts, oxidation products, N-oxide species, minor desalkyl or demethylated derivatives, salt-related counterions, residual solvents and trace inorganic residues; known metabolic derivatives and pharmacokinetic metabolites are also monitored for characterization but are not present at significant levels in properly manufactured API. Quality control employs validated HPLC and GC methods for organic impurities, LC-MS for structural confirmation, and limits for residual solvents and heavy metals in accordance with ICH guidance.
Tianeptine is prescribed primarily for treatment of major depressive disorder and may be used off-label for certain anxiety presentations; its clinical effects are attributed to modulation of glutamate signaling, enhancement of neuroplasticity, and additional receptor interactions that differ from SSRIs and classical tricyclic antidepressants.
No, morphine is a prototypical opioid analgesic with well characterized high intrinsic efficacy at the mu opioid receptor and greater analgesic potency per milligram; tianeptine has opioid receptor activity that may produce opioid-like effects at certain doses but it is not generally considered more potent than morphine.
No, tianeptine is not classified as a selective serotonin reuptake inhibitor. Although it affects serotonin reuptake in ways that were historically emphasized, its overall pharmacology is atypical and includes glutamatergic modulation, neuroplastic effects, and opioid receptor activity, distinguishing it from SSRIs.
Tianeptine acts as an agonist at mu opioid receptors and contributes to opioid-like pharmacology, but it is not routinely characterized as an identical full agonist to classic opioids such as morphine; its intrinsic efficacy at the receptor and clinical profile differ from standard full opioid agonists.
